Denub 60 mg/ml PFS Injection 2 x 1 ml

Denub 60 mg/ml PFS Injection 2 x 1 ml belongs to a group of medicines called RANK ligand inhibitors used to treat osteoporosis in postmenopausal women and men who have an increased risk of fracture. Denub 60 mg/ml PFS Injection 2 x 1 ml is also used to treat bone loss due to reduced testosterone level caused by surgery, due to the treatment with medicines such as glucocorticoids and in patients with prostate cancer. Denub 60 mg/ml PFS Injection 2 x 1 ml may also be used to reduce the risk of fractures in people with multiple myeloma, giant cell tumour of the bone, and to treat high calcium levels caused by cancer.
 
Denub 60 mg/ml PFS Injection 2 x 1 ml contains Denosumab, which works by blocking a receptor in the body that causes bone loss, thereby treating bone loss. Denub 60 mg/ml PFS Injection 2 x 1 ml treats giant cell tumour of bone (GCTB) by blocking certain receptors in the tumour cells, thereby slowing the growth of the tumour. Denub 60 mg/ml PFS Injection 2 x 1 ml helps treat high calcium levels by decreasing bone breakdown, as a breakdown of the bones releases calcium. Denub 60 mg/ml PFS Injection 2 x 1 ml makes the bones stronger and less likely to break.
 
Denub 60 mg/ml PFS Injection 2 x 1 ml will be administered by a healthcare professional; do not self-administer. Sometimes, you may experience common side effects such as bone/joint/muscle pain, arm/leg pain, abdominal discomfort, constipation, and painful/frequent urination. You should talk to your doctor if the side effects persist or worsen.
 
Denub 60 mg/ml PFS Injection 2 x 1 ml might cause jaw osteonecrosis; therefore, maintain good dental hygiene and receive regular dental check-ups whilst on treatment with Denub 60 mg/ml PFS Injection 2 x 1 ml. Avoid taking Denub 60 mg/ml PFS Injection 2 x 1 ml if you are pregnant. Consult your doctor before taking Denub 60 mg/ml PFS Injection 2 x 1 ml if you are breastfeeding. Denub 60 mg/ml PFS Injection 2 x 1 ml is not recommended for children below 18 years as safety and effectiveness have not been established. To rule out any interactions, keep your doctor informed about your health condition and medicines.

Denub 60 mg/ml PFS Injection 2 x 1 ml used to treat osteoporosis, bone loss, giant cell tumour of the bone, and high calcium levels. The detailed uses of Denub 60 mg/ml PFS Injection 2 x 1 ml are as follows:

• Management of Osteoporosis: Denub 60 mg/ml PFS Injection 2 x 1 ml treats osteoporosis in postmenopausal women, increasing bone density and reducing fracture risk.
• Giant cell tumour of the bone treatment: Denub 60 mg/ml PFS Injection 2 x 1 ml is prescribed for the treatment of giant cell tumour of the bone, which helps by reducing tumour size and slowing its growth.
• Increases bone mass: Denub 60 mg/ml PFS Injection 2 x 1 ml increases bone mass in patients at high risk for fracture, including those undergoing androgen deprivation therapy for prostate cancer or adjuvant aromatase inhibitor therapy for breast cancer.
• Hypercalcemia Treatment: Denub 60 mg/ml PFS Injection 2 x 1 ml treats hypercalcemia caused by cancer, helping normalise calcium levels in the blood.
• Paget’s Disease: Denub 60 mg/ml PFS Injection 2 x 1 ml treats Paget’s disease by alleviating bone pain and complications caused by enlarged and deformed bones.

• Your doctor will determine the dosage and timing of Denub 60 mg/ml PFS Injection 2 x 1 ml based on your health condition. Usually, it is given once every 6 months.
• Denub 60 mg/ml PFS Injection 2 x 1 ml is administered subcutaneously (under the skin) in your upper arm, upper thigh, or stomach area by the doctor or nurse in a hospital setting.
• Do not self-administer it.

Denub 60 mg/ml PFS Injection 2 x 1 ml belongs to a group of medicines called RANK ligand inhibitors used to treat osteoporosis in postmenopausal women and men who have an increased risk of fracture. Denub 60 mg/ml PFS Injection 2 x 1 ml is also used to treat bone loss due to reduced hormone levels caused by surgery or due to treatment with medicines in patients with prostate cancer. It is also used to treat bone loss occurring due to long-term treatment with glucocorticoids in patients who are at an increased risk of fractures. Denub 60 mg/ml PFS Injection 2 x 1 ml may also be used to reduce the risk of fractures in people with multiple myeloma, giant cell tumours of the bone and to treat high calcium levels caused by cancer. Denub 60 mg/ml PFS Injection 2 x 1 ml binds to a protein on RANK ligand on osteoclast (cells that cause bone breakdown) and inhibits their formation, functioning and survival. It decreases bone breakdown, increases bone density, and strengthens the bone. Denub 60 mg/ml PFS Injection 2 x 1 ml treats giant cell tumour of bone (GCTB) by blocking certain receptors in the tumour cells, thereby slowing the growth of the tumour. Denub 60 mg/ml PFS Injection 2 x 1 ml helps treat high calcium levels by decreasing bone breakdown, as the breakdown of the bones releases calcium. Denub 60 mg/ml PFS Injection 2 x 1 ml makes the bones stronger and less likely to break.

Do not take Denub 60 mg/ml PFS Injection 2 x 1 ml if you are allergic to any of its components or have hypocalcaemia (low levels of calcium in the blood). Inform your doctor if you have low levels of calcium, kidney dysfunction, liver problems, poor dental health, gum problems, weak immune system, hypoparathyroidism (decreased function of the parathyroid gland), malabsorption, latex allergy, undergone thyroid surgery, planned dental procedure, if you are taking glucocorticoids, or cannot take calcium and vitamin D supplements. Avoid taking Denub 60 mg/ml PFS Injection 2 x 1 ml if you are pregnant. Consult your doctor if you are breastfeeding. Denub 60 mg/ml PFS Injection 2 x 1 ml is not recommended for children below 18 years as safety and effectiveness have not been established.